2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nasdaq notified Roman DBDR Acquisition Corp. II on August 19, 2026, that it does not maintain the minimum of 400 holders required for continued listing. The notice has no immediate effect on the listing of the company's securities on the Nasdaq Global Market, but the company must submit a compliance plan, and failure to regain compliance could ultimately lead to delisting.
Nasdaq deficiency letter received August 19, 2026, under Listing Rule 5450(a)(2)
Compliance plan due to Nasdaq by October 5, 2026
If the plan is accepted, Nasdaq can grant an exception until February 15, 2027
If Nasdaq rejects the plan, the company may appeal to a Nasdaq Hearings Panel
On August 20, 2026, subsidiary Starling Oncology Management, LLC entered a revolving credit agreement with Gemino Healthcare Finance, LLC (d/b/a SLR Healthcare ABL) for up to $25 million. The filing says the company is not required or expected to borrow the full amount, and that it is intended to provide financial flexibility if needed. Shareholders should note the facility is secured by substantially all of the subsidiary's assets and carries a covenant on loan turn days.
Facility of up to $25 million, dated August 20, 2026, maturing August 20, 2029
Interest at Term SOFR plus 3.95%, with Term SOFR floored at 2.00% per annum
$4,750,000 outstanding as of August 21, 2026 (the filing text reads "$4,750,000 million")
Secured by a first-priority security interest in substantially all of the subsidiary's collateral; covenant limits Maximum Loan Turn Days to 35 on a rolling three-month basis
Nerdy Inc. said on August 20, 2026, that it had notified Chief Operating Officer John Paszterko of its decision to end his service in that role, effective immediately. The filing does not give a reason for the decision or name a successor, so shareholders have no stated information on how operations leadership will be handled.
The Company notified John Paszterko of the decision on August 20, 2026.
His service as Chief Operating Officer ends effective immediately.
The filing does not state a reason for the change or name a replacement.
The 8-K was signed on August 21, 2026, by Chief Legal Officer and Corporate Secretary Christopher C. Swenson.
GEE Group entered a cooperation agreement with Star Equity Fund on August 21, 2026. Star Equity Fund withdrew its director nominee and its proposal to remove two directors at the 2026 Annual Meeting, and agreed to standstill and voting commitments. The company agreed to phase in declassification of its board, which will change how directors are elected going forward.
Star Equity Fund withdrew its director nominee and its business proposal to remove two GEE Group directors at the 2026 Annual Meeting.
Star Equity Fund agreed not to acquire more than 7.5% of outstanding Common Stock and to other customary standstill terms.
A majority of the board will be declassified at the 2027 Annual Meeting and the board will be fully declassified at the 2028 Annual Meeting, per the press release.
The agreement ends on the earlier of the opening of the advance notice period for 2027 director nominations or 120 days before the one-year anniversary of the 2026 Annual Meeting.
Global Water Resources agreed on August 20, 2026 to sell 1,129,944 shares of common stock at $8.85 per share, for about $10 million in total, in a private placement. The buyers include Levine Investments Limited Partnership and Andrew M. Cohn, who are linked to directors Jonathan L. Levine and Andrew M. Cohn, so existing shareholders should note that insiders are among the purchasers and that the new shares add to the shares outstanding.
1,129,944 shares of common stock sold at $8.85 per share, about $10 million in aggregate, under a Securities Purchase Agreement dated August 20, 2026
Sold in a private placement exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506; all purchasers are accredited investors
Purchasers include Levine Investments Limited Partnership and Andrew M. Cohn; director Jonathan L. Levine is a limited partner of the partnership and director of its general partner, Keim Inc., and director Andrew M. Cohn is its Director of
Price set at the Nasdaq closing bid price immediately before the agreement was entered into
SolarMax Technology received a Nasdaq notice on August 20, 2026, because it has not filed its Form 10-Q for the quarter ended June 30, 2026. The company has until October 19, 2026 to submit a plan to regain compliance, and Nasdaq could grant an exception to February 16, 2027 if it accepts that plan. The filing also discloses two earlier Nasdaq deficiencies, a bid price issue and a market value of listed securities issue, so shareholders face several open listing requirements at once.
Nasdaq notice dated August 20, 2026 cites Listing Rule 5250(c)(1) for the missing 10-Q for the quarter ended June 30, 2026
Plan to regain compliance due October 19, 2026; Nasdaq could allow an exception up to February 16, 2027 if the plan is accepted
Bid price deficiency notice received March 3, 2026; compliance deadline August 31, 2026; one-for-12 reverse stock split effected August 13, 2026
Market value of listed securities notice received June 22, 2026; compliance deadline December 21, 2026
Mangoceuticals and Nuclea Energy mutually agreed on August 19, 2026 to terminate their Business Combination Agreement, which had been dated July 29, 2026. The parties said the $15,000,000 PIPE financing minimum could not be raised by the August 21, 2026 outside date, so the financing closing condition could not be met on the agreed terms.
Termination agreed August 19, 2026 under Section 12.1(a) of the agreement, which was dated July 29, 2026
Closing required PIPE financing of at least $15,000,000 deposited into escrow; the outside date was August 21, 2026
Each party bears its own costs, and the parties exchanged mutual releases except for willful breaches before termination
Northrop Grumman's independent directors approved a one-time performance-based equity grant to Chair, CEO and President Kathy J. Warden on August 19, 2026. The award pays out based on the company's absolute stock price change through December 31, 2031, and is tied to her continued service, which links her pay directly to shareholder returns.
Award approved by independent directors on August 19, 2026; disclosed in an 8-K dated August 21, 2026
Target award is 35,910 Market Stock Units (MSUs), with payout ranging from 0% to 150% of target
Performance period ends December 31, 2031; full target payout requires at least 10% stock price appreciation
Payout is 0% if the stock falls more than 25% and 150% if it rises 50% or more
Pasithea Therapeutics Corp. received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, moving the deadline from August 19, 2026 to February 16, 2027. The company says it may consider a reverse stock split, and if it does not regain compliance, Nasdaq could begin delisting proceedings, though the company says there is no assurance it will meet the new deadline.
Nasdaq letter dated February 20, 2026 flagged closing bid price below $1.00 for 30 consecutive business days.
Original compliance deadline was August 19, 2026; extension granted in an August 20, 2026 Nasdaq letter to February 16, 2027.
Company may consider a reverse stock split; if not compliant by the deadline, Nasdaq would issue a delisting notice that the company could appeal to a hearings panel.
Elutia completed the sale of its SimpliDerm breast reconstruction business, which made up substantially all of its Women's Health segment, to Cellution Biologics on August 17, 2026. The company received $7.7 million in cash at closing, subject to post-closing adjustments, with up to $3 million more in contingent payments. The filing says the company's 2025 and first-half 2026 pro forma continuing operations exclude the business, which had accounted for most of its reported net sales.
Net cash received at closing: $7.7 million, subject to post-closing inventory adjustments
Contingent payments of up to $3 million over the next 18 months, tied to technology transfer and commercial milestones
Pro forma six-month 2026 net sales from continuing operations: $2.2 million, versus $5.5 million as reported
Company expects to record an estimated gain of $4.9 million, which is not reflected in the pro forma periods
Estrella Immunopharma received a Nasdaq notice on August 17, 2026, stating its common stock closed below $1.00 for 30 consecutive business days, so it no longer meets the minimum bid price requirement. The notice has no immediate effect on trading, and the company has until February 16, 2027 to regain compliance, which could involve a reverse stock split.
Nasdaq letter dated August 17, 2026 cites closing bid price below $1.00 from July 6, 2026 through August 14, 2026
Compliance period runs 180 calendar days, until February 16, 2027
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
If not compliant by the deadline, the company may be eligible for a second 180-day period, or face delisting notice and an appeal
NexGel terminated CEO Adam R. Levy without Cause effective August 21, 2026, and Levy resigned from the Board. The Board appointed director Brian Kieser as Interim CEO, and formed a Special Committee to review strategic alternatives, liquidity and non-core assets.
Levy's employment was terminated without Cause effective August 21, 2026; he also resigned from the Board and all other company positions.
Brian Kieser, a Board member since May 6, 2026, is Interim CEO. He is also CEO of Sequence LifeScience, which has a strategic partnership with NexGel.
The Special Committee, chaired by Kevin Harris with Steve Glassman, expects to present a strategic and value creation framework to the Board within 30 to 45 days.
The separation agreement with Levy and Kieser's compensation terms have not been finalized; the company will file an 8-K amendment once they are.
Nuvectis Pharma entered an agreement with Jefferies LLC on August 21, 2026, allowing it to sell up to $200 million of common stock through a new shelf registration. The company also ended its prior at-the-market program on July 20, 2026. Sales are not guaranteed, and shareholders could face dilution if shares are sold.
Open Market Sale Agreement with Jefferies LLC as sales agent, dated August 21, 2026
New Form S-3 shelf registration covering $200 million in securities, filed August 21, 2026
Jefferies fee of up to 3.0% of gross proceeds from ATM share sales
Prior at-the-market program terminated July 20, 2026; no further sales under it
On August 21, 2026, Alexandria Real Estate Equities issued and sold $1 billion of 7.250% Series A Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057 in a registered public offering. The notes are unsecured, rank below all existing and future senior debt, and carry a rate that resets after February 15, 2032, which adds a long-term debt obligation for shareholders to weigh.
Principal amount: $1,000,000,000 of notes, issued and sold on August 21, 2026
Interest at 7.250% per year until February 15, 2032, then resets to the five-year U.S. Treasury rate plus 2.889%, with the rate not resetting below 7.250%
Interest payable semi-annually on February 15 and August 15, beginning February 15, 2027; notes mature February 15, 2057
Notes are junior subordinated and guaranteed on a subordinated unsecured basis by Alexandria Real Estate Equities, L.P.; trustee is U.S. Bank Trust Company, National Association
Rain Enhancement Technologies Holdco received a Nasdaq notice on August 18, 2026 stating it had not regained compliance with the $35 million market value of listed securities requirement. Unless the company obtained a hearing, its shares would face suspension and delisting from the Nasdaq Capital Market on August 27, 2026. The company requested a hearing before the Nasdaq Hearings Panel on August 21, 2026, and expects this to stay any delisting action, but the filing says the panel may not grant continued listing.
Nasdaq notice received August 18, 2026 said the company had not regained compliance with the $35,000,000 MVLS threshold.
Compliance deadline was August 17, 2026, after a 180-calendar-day period that started with a February 18, 2026 notice.
Company requested a hearing before the Nasdaq Hearings Panel on August 21, 2026.
Scheduled suspension and delisting date is August 27, 2026, unless a stay applies; the company says there is no assurance the panel will grant continued listing.
loanDepot, Inc. (NYSE: LDI) received a written notice from the New York Stock Exchange on August 21, 2026, saying its Class A common stock failed the $1.00 minimum price standard because its average closing price was below $1.00 over 30 consecutive trading days. The company has six months to regain compliance, and if it cannot, the NYSE will begin procedures to suspend and delist the stock, which matters to shareholders because it sets a firm deadline for a share price recovery or a possible reverse stock split.
The NYSE notice was received August 21, 2026, and the company said the average closing price was below $1.00 as of August 20, 2026.
The company has a six-month cure period to bring its share price and average share price back to at least $1.00.
The company must notify the NYSE of its intent to cure within 10 business days of receiving the notice.
A reverse stock split is among the options the company will consider; it would need stockholder approval no later than the next annual meeting, anticipated for early June 2027.
Hinge Health entered an office lease on August 18, 2026 for about 119,278 rentable square feet at 300 Mission Street in San Francisco. Estimated base rent over the term is about $86.0 million, plus operating costs, and the lease is expected to expire February 28, 2037.
Estimated base rent over the lease term is about $86.0 million, plus the company's share of operating expenses, taxes and insurance
Landlord provides a tenant improvement allowance of up to $17.9 million
Company must post a $2.8 million irrevocable standby letter of credit to secure the lease
One five-year renewal option and a one-time early termination right effective January 31, 2035, subject to conditions including a termination payment
Evolution Petroleum completed its previously announced acquisition of mineral and royalty interests in the Midland Basin, Texas, on August 20, 2026, for a total purchase price of $16 million, subject to customary post-closing adjustments. The company says the interests are expected to generate about $3.9 million of next-twelve-month asset-level cash flow and that the deal is immediately accretive to cash flow per share, though these are management estimates.
Total purchase price of $16 million, with an effective date of August 1, 2026
Interests span about 3,420 net royalty acres across five Texas counties and include royalties on an estimated 832 producing wells
Expected next-twelve-month asset-level cash flow of about $3.9 million, an acquisition multiple of about 4.1x, per company estimate
Funded with net proceeds from a recent public stock offering, cash on hand and revolver borrowings; pro forma liquidity about $19 million
Enova's subsidiary NetCredit Combined Receivables B, LLC issued $300,886,000 in 2026-A Notes on August 21, 2026, secured by about $316.72 million of unsecured consumer installment loans. The notes carry fixed coupons from 5.88% to 10.64% and mature September 20, 2032, and are obligations of the issuer only, not guaranteed by Enova. The filing describes a debt financing, and it does not state any effect on Enova's earnings or guidance.
Issued $300,886,000 of notes: $240,709,000 Class A, $44,341,000 Class B, $15,836,000 Class C
Fixed coupons: Class A 5.88%, Class B 7.68%, Class C 10.64% per annum
Final maturity September 20, 2032; indenture trustee is Citibank, N.A.
Notes are not guaranteed by Enova and were sold only to qualified institutional buyers and non-U.S. persons
Global Interactive Technologies (GITS) received a Nasdaq notice on August 20, 2026, because it did not timely file its Form 10-Q for the quarter ended June 30, 2026, which Nasdaq Listing Rule 5250(c)(1) requires for continued listing. The company says it expects to file the 10-Q promptly, and its common stock will remain listed and traded during the 60-day grace period.
Nasdaq notice received August 20, 2026, for not timely filing the Form 10-Q for the quarter ended June 30, 2026
Company has 60 calendar days from the notice date to submit a plan to regain compliance
If Nasdaq accepts the plan, an exception of up to 180 days from the 10-Q due date, or until February 16, 2027, is possible
Common stock continues to trade on Nasdaq during the grace period, subject to other listing requirements
On August 20, 2026, Palo Alto Networks' board approved an Executive Change in Control and Severance Policy covering senior vice presidents and above, including CEO Nikesh Arora and CFO Dipak Golechha. The board also adopted amended and restated bylaws, mainly to align with Delaware law and update routine governance provisions. The filing sets out severance terms but no financial results, so its direct effect on shareholders depends on whether a change in control occurs.
Policy covers executives including CEO Nikesh Arora, CFO Dipak Golechha, President William "BJ" Jenkins and Chief Product and Technology Officer Lee Klarich
CEO severance outside a change-in-control period, after a change in control, or for Good Reason: 200% of salary and 200% of target cash incentive, plus 24 months of health benefits; other executive officers receive 150% and 18 months
Amended and Restated Bylaws took effect immediately on August 20, 2026, and include updates to special board meeting authority and indemnification provisions
Citius Pharmaceuticals received a Nasdaq extension until February 8, 2027 to show its stock closes at or above $1.00 per share, a continued listing requirement. The filing says the extension has no effect on the current listing, but if compliance is not regained by that date, Nasdaq will issue a delisting notice and the company may appeal.
Nasdaq granted an extension to February 8, 2027 for the $1.00 per share bid price requirement under Rule 5550(a)(2)
Compliance requires a closing bid of $1.00 or more for at least ten consecutive business days before February 8, 2027
Common stock will continue trading on the Nasdaq Capital Market under CTXR for now
The company says there can be no assurance it will regain compliance
Adient entered an amendment on August 20, 2026 to its term loan credit agreement, adding $500 million of incremental term loans that bring total loans outstanding to $1.12 billion. The proceeds, with cash on hand, will redeem all $500 million of the 7.000% Senior Secured Notes due 2028 and cover fees and expenses. The filing does not describe a change in the company's operating results.
Amendment dated August 20, 2026 adds $500 million of incremental term loans under the Term Loan Credit Agreement dated May 6, 2019.
Total loans outstanding under the amended credit agreement are $1.12 billion as of the amendment date.
Proceeds plus cash on hand will redeem all $500 million of Adient Global Holdings' 7.000% Senior Secured Notes due 2028.
Incremental term loans have the same maturity and terms as existing term loans and remain secured guarantees by Parent and certain subsidiaries.
WhiteFiber completed a $310.0 million private offering of 5.00% convertible senior notes due 2032 on August 21, 2026, including the full $40.0 million option. The company used about $118.5 million of the roughly $298.5 million in net proceeds to exchange $198.15 million of its 4.500% notes due 2031 for cash and about 6.3 million ordinary shares. The new notes add debt and could dilute shareholders on conversion, which the company can settle in cash, shares, or both, and the filing says more project financing will be needed.
$310.0 million principal of 5.00% notes maturing September 1, 2032, with semiannual interest starting March 1, 2027
Initial conversion price of about $33.84 per share, a premium of about 25% over the August 18, 2026 last sale price
Exchanged $198.15 million of 4.500% notes due 2031 for about $118.5 million cash and about 6.3 million ordinary shares, leaving about $31.85 million outstanding
Net proceeds of about $298.5 million; the company says it will require additional project financing, such as construction loans
Breeze Acquisition Corp. II received a Nasdaq notice on August 20, 2026, saying it no longer complies with listing rules because it has not filed its Form 10-Q reports for the quarters ended March 31 and June 30, 2026. The notice has no immediate effect on the listing or trading of the company's securities, but the company must submit a plan to regain compliance by September 21, 2026, and Nasdaq may grant an exception to December 28, 2026, with no assurance that this will happen.
Nasdaq notice received August 20, 2026, citing Listing Rule 5250(c)(1) for late periodic filings
Delinquent Form 10-Qs cover the periods ended March 31, 2026 and June 30, 2026
Compliance plan due September 21, 2026; Nasdaq may grant an exception until December 28, 2026 if the plan is accepted
Notice has no immediate effect on listing or trading; company says it does not assure compliance within the required period
Effective August 17, 2026, Nu Skin said Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence. Chayce Clark, the company's Executive Vice President, Chief Operating Officer and Chief Legal Officer, will lead Mr. Keisel's organization during his absence. The filing does not state how long the leave will last, so shareholders have no stated return date for the sales leadership role.
Effective date of leave: August 17, 2026
Justin Keisel, EVP and President of Global Sales, began a medical leave of absence
Chayce Clark, EVP, COO and Chief Legal Officer, will lead Keisel's organization during the leave
DarioHealth said President and Chief Commercial Officer Steven Nelson will stop serving in that role on September 1, 2026, and his employment ends September 30, 2026, under a separation agreement signed August 20, 2026. Nelson will then provide consulting services through December 31, 2027, for which the company plans to grant him 30,000 restricted shares, subject to Compensation Committee approval.
Nelson ceases as President and Chief Commercial Officer effective September 1, 2026; employment ends September 30, 2026.
Company will reimburse up to three months of COBRA health coverage at $2,600 per month after the separation date.
Consulting agreement effective October 1, 2026, runs through December 31, 2027, with a grant of 30,000 restricted shares, subject to Compensation Committee approval.
Chaince Digital Holdings Inc. entered into an at-the-market offering agreement on August 19, 2026, allowing it to sell up to $300 million of its ordinary shares through H.C. Wainwright & Co. as sales agent. The filing states the company has no obligation to sell any shares, and the sales agent commission is 3.0% of gross sales, so the program could dilute existing shareholders if used.
Program size: up to $300,000,000 of ordinary shares, par value $0.004 per share
Sales agent: H.C. Wainwright & Co., LLC, paid a 3.0% commission on gross sales price
Company has no obligation to sell shares; it may terminate on ten business days' notice
Issuance runs under Form F-3 shelf (File No. 333-287428) effective June 27, 2025; prospectus supplement filed August 21, 2026
VivoSim Labs (VIVS) received a Nasdaq notice on August 17, 2026 saying its stock no longer met the $1 minimum bid price over 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance, and its shares continue to trade on the Nasdaq Capital Market for now. The company has proposed a reverse stock split, which requires stockholder approval, and a failure to regain compliance could lead to delisting proceedings.
Nasdaq notice received August 17, 2026 under Listing Rule 5550(a)(2) for the $1 minimum bid price
Compliance deadline is February 16, 2027; regaining it requires a closing bid of at least $1 for ten consecutive business days
Proposed reverse stock split ratio range of 1-for-5 to 1-for-20, subject to stockholder approval in the 2026 annual meeting proxy
Notice has no immediate effect on listing or trading; ticker remains VIVS
Insteel Industries will close its Upper Sandusky, Ohio welded wire facility and move manufacturing to its remaining welded wire plants, with operations expected to cease by the end of October 2026. The company expects restructuring charges of about $4.6 million, and says the move is not expected to affect its revenue.
Up to 65 positions to be eliminated at the Upper Sandusky facility
Operations expected to cease by the end of October 2026
Expected restructuring charge of approximately $4.6 million, including $1.0 million asset impairment
Cash charges expected to begin in the first quarter of fiscal 2027
RenX Enterprises Corp. disclosed that its 50%-owned Norman Berry II Owner, LLC agreed on August 17, 2026 to sell an approximately 7.7-acre property in East Point, Georgia, for $2.6 million to Arbour Valley Development, LLC. Closing depends on conditions including the purchaser receiving state tax credit allocations and obtaining financing, and the company says there is no assurance the sale will close. If it closes as expected, about $800,000 would repay two notes the company holds against the property, and the company's 50% share of the remaining proceeds is expected to be about $900,000.
Purchase price is $2.6 million; the agreement is effective August 17, 2026.
Earnest money deposits of $60,000 each are payable under the agreement, and the sale terminates if the purchaser does not obtain the tax credit allocation it requested.
Purchaser must notify the seller by September 25, 2026 if it will not submit a state application, and has 180 days after the application period to secure financing.
Expected closing proceeds: about $800,000 to repay two notes; about $1.8 million remaining, with RenX's 50% share about $900,000.
Mesa Royalty Trust said on August 21, 2026 that it will pay no distribution for August 2026, because costs, charges and expenses attributable to its royalty properties exceeded the revenue received from the sale of production reported by the working interest owners. The trust also said distributions are expected to be materially reduced until its cash reserves reach $2.0 million, and that accumulated excess production costs will reduce future distributions and may in some periods result in none.
No distribution will be paid for August 2026.
Royalty-property costs and expenses exceeded reported revenue from oil, natural gas and other hydrocarbon sales.
Distributions are expected to be materially reduced until the trust's cash reserves total $2.0 million, per its most recent Form 10-Q.
Substantial accumulated excess production costs will decrease future distributions and may result in none in some periods.
The Buckle reported results for the fiscal quarter ended August 1, 2026. Net sales rose 4.6% to $319.8 million, but net income fell to $44.4 million, or $0.87 per diluted share, from $45.0 million, or $0.89 per diluted share, a year earlier. Revenue growth was positive while profit declined slightly, so shareholders see higher sales alongside slightly lower earnings.
Q2 net sales up 4.6% to $319.8 million from $305.7 million; comparable store net sales up 2.1%
Q2 net income $44.4 million ($0.87 diluted EPS) versus $45.0 million ($0.89 diluted EPS) a year earlier
26-week net income $91.3 million ($1.79 diluted EPS) versus $80.2 million ($1.59 diluted EPS) in the prior-year period
Store count was 446 at quarter end versus 440 a year earlier
On August 19, 2026, Woodward agreed to sell $450 million of senior unsecured notes in three $150 million series, due in 2029, 2030 and 2033, in private placements. The closing is scheduled for September 30, 2026, and the notes add new debt that shareholders should weigh against the company's leverage covenants and interest costs.
Series U notes ($150 million) due September 30, 2029 at 5.34%; Series V ($150 million) due September 30, 2030 at 5.39%; Series W ($150 million) due September 30, 2033 at 5.64%
Rates rise by 0.75 percentage points (to 6.09%, 6.14% and 6.39%) for any fiscal quarter after one ending with debt to EBITDA above 3.5 to 1.0
Closing scheduled for September 30, 2026; interest paid semi-annually starting March 30, 2027
Obligations guaranteed by wholly owned subsidiaries MPC Products Corporation and Woodward HRT, Inc.
PermRock Royalty Trust declared a monthly cash distribution of $265,001.53, or $0.021782 per Trust Unit, to holders of record on August 31, 2026, payable September 15, 2026, based mainly on June 2026 production. The filing shows lower oil cash receipts and higher operating expenses than the prior month, which reduce the net profits available to the Trust and its unitholders.
Distribution: $265,001.53 total, $0.021782 per Trust Unit; record date August 31, 2026; payment date September 15, 2026
Oil cash receipts were $1.42 million, down $0.16 million from the prior month, mainly due to lower oil prices
Average oil price was $88.13 per barrel, versus $104.89 in the prior month
Total direct operating expenses rose $0.17 million to $0.66 million, mainly from higher lease operating and workover expenses
Marine Petroleum Trust declared a quarterly cash distribution of $0.095378 per unit, payable September 28, 2026, to unitholders of record on August 31, 2026. The payment is lower than the $0.096470 per unit paid last quarter, which the trust attributed to lower oil and natural gas production volumes, but higher than the $0.068097 per unit paid in the same quarter of 2025.
Distribution of $0.095378 per unit, payable September 28, 2026, to holders of record on August 31, 2026
Down from $0.096470 per unit last quarter; up from $0.068097 per unit in the same quarter of 2025
Versus last quarter: production volume decreased and oil prices realized increased, while natural gas prices realized decreased
Versus the same quarter of 2025: production volume and oil prices realized increased, while natural gas prices realized decreased
Solésence said on August 17, 2026 that its previously issued financial statements from December 31, 2023 through March 31, 2026 should no longer be relied upon and must be restated. The errors involved how labor and overhead were allocated to inventory, which overstated inventories and misstated cost of revenue, and the filing says the errors also affected gross profit, net income (loss), earnings per share and stockholders' equity.
Ten periods are affected, from December 31, 2023 through March 31, 2026, per the Audit Committee, Board and executive officers' August 17, 2026 conclusion.
The errors relate to labor and overhead allocation in inventories, which the company says did not comply with ASC 330 inventory-costing requirements.
The company expects to amend its 10-K reports for 2023, 2024 and 2025 and several 10-Q reports in the coming weeks.
The 8-K is dated August 20, 2026, and was signed by CFO Laura Riffner; the Audit Committee discussed the matters with its independent accountant.
Waters disclosed that Robert L. Carpio III resigned as Senior Vice President of its Analytical Sciences Division to pursue other opportunities, relinquishing his duties on August 20, 2026. Tina Wu, currently SVP of Materials Sciences and President, China, will take over the Analytical Sciences role, a leadership change in a business unit.
Robert L. Carpio III notified Waters on August 17, 2026 of his resignation as SVP, Waters Analytical Sciences Division.
Carpio relinquished his duties effective August 20, 2026.
Tina Wu, SVP, Waters Materials Sciences Division and President, China, will assume the Analytical Sciences SVP role.
Wu joined Waters in June 2026 after more than 20 years at DuPont, most recently as Global Vice President and President of DuPont Mobility & Materials since 2021.
First Interstate BancSystem announced that Jeff Lee, 57, will join as Executive Vice President and Chief Operations Officer of the company and First Interstate Bank, with a formal start expected on September 14, 2026. The filing sets an initial base salary of $480,000 and an expected restricted stock unit award with a $200,000 grant date value, which is a routine executive hiring step for shareholders.
Jeff Lee, 57, to become EVP and Chief Operations Officer; start expected September 14, 2026
Initial annual base salary set at $480,000
Expected time-based restricted stock units with $200,000 grant date value, vesting in three annual installments beginning September 14, 2027
Lee was an independent strategic consultant from March 2025 to November 2025; previously held roles at Seacoast Banking Corporation of Florida until January 2024
Sky Quarry Inc. appointed Heidi C. Bowman as its Chief Financial Officer, effective immediately, under an offer letter dated August 18, 2026. The filing gives her base salary and bonus eligibility, and it describes her background in strategic finance and prior CFO roles at investment firms and portfolio companies.
Heidi C. Bowman, 60, named Chief Financial Officer, reporting to the Chief Executive Officer
Base salary of $18,500 per month; eligible for quarterly bonuses in cash, equity, or both, at the Compensation Committee's discretion
Employment is at-will; either party may terminate with at least thirty days' written notice
Previously served as CFO of Hillair Capital from May 2010 to December 2025
On August 21, 2026, Werewolf Therapeutics agreed to merge with Ambros Therapeutics, a clinical-stage biotechnology company developing neridronate for CRPS-1, in an all-stock transaction. Pre-merger Werewolf stockholders, other than private placement investors, are expected to own about 6.8% of the combined company, so the merger would substantially dilute their holdings. The deal is expected to close by the first quarter of 2027, subject to stockholder approvals, Nasdaq listing approval, an effective Form S-4 and other conditions.
Pre-merger Ambros stockholders are expected to own about 71.7% of the combined company, and private placement investors about 21.5%.
Implied valuations are $500.0 million for Ambros and $47.5 million for Werewolf.
A concurrent private placement of $150 million in gross proceeds is expected to close with the merger.
Termination fees are $20.0 million payable by Ambros and $1.9 million payable by Werewolf in certain circumstances.
Odysight.ai agreed on August 20, 2026 to sell 3,437,500 shares of common stock at $3.20 each in an underwritten public offering led by Roth Capital Partners, with gross proceeds expected to be $11 million before fees and expenses. The same day, the company terminated its June 5, 2026 at-the-market sales agreement with Roth, which had a capacity of up to $20 million and made no sales. The new offering adds shares outstanding and dilutes existing holders, while the company says proceeds will fund research and development, sales and marketing, and working capital.
Firm offering of 3,437,500 shares at $3.20 per share; closing expected on or about August 21, 2026.
Underwriters have a 30-day option to buy up to 515,625 additional shares.
Underwriting discount is 6.5% of gross proceeds; company will reimburse up to $75,000 of Roth's expenses.
Company and its directors and executive officers agreed to a 45-day lock-up on sales of common stock, with exceptions.
Latham Group subsidiaries entered into a new Credit Agreement on August 20, 2026, providing a $75 million revolving credit line and a $300 million term loan from Jefferies Finance LLC as administrative agent. Proceeds were used to repay and terminate the existing February 23, 2022 credit agreement with Barclays Bank PLC. The new debt is secured by substantially all assets of the borrower and guarantors, and the filing does not state a change in total debt beyond the facilities themselves.
Revolving credit line of $75 million, maturing August 20, 2031, with interest based on SOFR, CORRA, EURIBOR or BBSY plus margins of 2.25% to 3.50%
Term loan of $300 million, maturing August 20, 2033, priced at Term SOFR plus 4.00% or Alternate Base Rate plus 3.00%, with 0.25% quarterly amortization
Proceeds used to repay and terminate the Credit and Guaranty Agreement dated February 23, 2022 with Barclays Bank PLC as agent
Springing maximum First Lien Net Leverage Ratio of 5.20:1.00 applies if revolver usage exceeds 40% of commitments at quarter-end
Lyntris Inc. priced its initial public offering on August 18, 2026, at $17.50 per share, with 5,714,286 shares sold by the company and 11,285,714 by selling stockholders. The company says net proceeds of approximately $69.5 million will be used mainly to repay about $60.0 million of indebtedness, and the company received no proceeds from the selling stockholders' shares. The filing also sets a 180-day to 720-day staggered lock-up for directors, officers and substantially all shareholders, and names new directors and a new chairman and vice chairman.
IPO priced at $17.50 per share for 17,000,000 total shares; the IPO closed and shares were delivered on August 20, 2026
Company expects net proceeds of approximately $69.5 million and plans to repay about $60.0 million of indebtedness
Seven directors appointed upon IPO effectiveness; David Stinnett named Chairman and Matthew Alty named Vice Chairman
Underwriters hold a 30-day option for up to 2,550,000 additional shares from certain selling stockholders
Sky Harbour Group entered a stock purchase agreement with M-COR Capital LLC to sell 1,000,000 Class A common shares at $10.00 each in a registered direct offering. The company expects gross proceeds of about $10.0 million before offering expenses, with closing on or before August 26, 2026, and plans to use the proceeds for general corporate purposes. The sale adds new shares outstanding, which dilutes existing holders, though the filing does not give the share count outstanding.
Sale of 1,000,000 Class A common shares at $10.00 per share to M-COR Capital LLC
Expected gross proceeds of approximately $10.0 million before offering-related expenses
Expected closing on or before August 26, 2026; proceeds for general corporate purposes, per the press release for future hangar developments
Offering is made under an effective Form S-3 shelf registration (No. 333-278275)
On August 20, 2026, Universal Health Services completed a public offering of $600 million of 5.500% senior secured notes due 2031 and $500 million of 6.000% senior secured notes due 2036. The notes are guaranteed by subsidiaries and secured by first-priority liens on certain assets, ranking equally with the company's senior secured credit facility and five series of existing secured notes. The filing adds $1.1 billion of secured debt, and notes that some underwriter affiliates will receive proceeds as repayment of revolving credit facility borrowings.
$600 million 5.500% senior secured notes mature September 1, 2031; callable before August 1, 2031 at par plus accrued interest and a make-whole premium.
$500 million 6.000% senior secured notes mature September 1, 2036; callable before June 1, 2036 at par plus accrued interest and a make-whole premium.
Interest is payable semi-annually on March 1 and September 1, starting March 1, 2027.
Moody's and S&P rated the notes investment grade at issuance, but the filing says collateral release conditions were not met as of that date.
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to buy back up to $230 million of its common shares, at $5.00 to $5.75 per share, funded from cash on hand. The offer has not yet commenced and is subject to exemptive relief, so its terms and completion are not assured, but it would return proceeds from the Moderna settlement to shareholders.
Offer to repurchase up to $230 million of common shares at not less than $5.00 and not more than $5.75 per share, in cash
Expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, unless extended or terminated
Funded through the company's cash on hand; commencement depends on obtaining exemptive relief under Canadian and US securities laws
Follows the March 2026 Moderna settlement and a July 2026 initial payment under that settlement
Intercontinental Exchange entered new financing tied to its pending acquisition of MarketAxess Holdings, including a $2.0 billion delayed draw term loan and amendments to its $3.9 billion revolving credit facility. The filing also shows the company issued $3.73 billion in senior unsecured notes, which permanently reduced its $6.2 billion bridge facility to zero, so the acquisition is now backed by these new sources rather than the bridge.
Term loan facility of $2.0 billion with Bank of America as administrative agent, maturing 24 months after funding
Revolving credit facility extended to August 20, 2031 for consenting lenders with $3.67 billion in commitments, and a new $1.5 billion MarketAxess revolving commitment class
Senior unsecured notes issued August 20, 2026 for gross proceeds of $3.73 billion; $6.2 billion bridge facility reduced to $0
Qnity Electronics appointed Ken Rizvi as Senior Vice President and Chief Financial Officer, effective October 1, 2026. Rizvi was most recently CFO of Synaptics, a role he has held since July 2024, and Michael Goss, the current interim CFO, will move to Vice President, Finance & Controllership and Principal Accounting Officer. The filing discloses a $10.0 million equity buyout award and a $600,000 base salary for Rizvi, but no financial results or guidance.
Ken Rizvi becomes Senior Vice President and CFO effective October 1, 2026.
Michael Goss stops serving as interim CFO on the effective date and becomes Vice President, Finance & Controllership and Principal Accounting Officer.
Rizvi's package includes a $600,000 annual base salary, a 90% target short-term incentive, and a $10.0 million equity buyout award split 60% restricted stock units and 40% performance stock units.
Rizvi also receives a 2026 annual long-term incentive award valued at $5.5 million.
Ubiquiti reported fourth-quarter fiscal 2026 revenue of $937.3 million, up 23.5% from a year earlier, with GAAP diluted EPS of $4.70 versus $4.41. The company also declared a $1.00 per share dividend and extended its $500 million stock repurchase program to September 30, 2027.
Q4 fiscal 2026 (ended June 30, 2026) revenue was $937.3 million, up from $759.2 million a year earlier and $788.2 million in the prior quarter.
Non-GAAP diluted EPS was $4.73, versus $3.54 a year earlier; the prior-year GAAP results included a $53.7 million deferred tax benefit.
Gross margin was 45.8%, down from 47.0% in the prior quarter but up from 45.1% a year earlier.
Board declared a $1.00 per share dividend payable September 8, 2026, to holders of record on August 31, 2026; the $500 million buyback now runs through September 30, 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.